IFNA2 and hepatitis C virus infection: Two other large, randomized trials investigated the efficacy of adjuvant interferon alfa-2b (IFNα-2b) therapy in patients with resected HCC driven by hepatitis C, and concluded that adjuvant IFNα-2b did not reduce recurrence with a higher prevalence of treatment-related toxicity.